Compare KIO & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIO | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 472.9M |
| IPO Year | 2011 | 2015 |
| Metric | KIO | ZVRA |
|---|---|---|
| Price | $11.24 | $8.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 252.5K | ★ 550.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.69 | $6.19 |
| 52 Week High | $12.83 | $13.16 |
| Indicator | KIO | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 23.73 | 53.84 |
| Support Level | N/A | $8.61 |
| Resistance Level | $12.15 | $9.03 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 19.49 | 69.51 |
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.